ABSTRACT
Objective To compare the content of main constituents of Compound Wurenchun Capsules dissolved in serum and plasma of rats. Methods Serum and plasma containing drug were prepared after ig the preparation to rats. Lichrosphere C_ 18 (250 mm?4.6 mm, 5 ?m) column and Phenomenex Description C_ 18 (4.0 mm?3.0 mm) protective column were used. The mobile phase consisted of methanol-water, eluted in gradient mode. The flow rate was 1.0 mL/min. The column temperature was 30 ℃ and detection wavelength was 254 nm. Results The linear ranges of schisandrin and schisandrin B were 0.051 2 .614 4 and 0.039 8—0.477 6 ?g. The average relative recoveries of schinsandrin and schisandrin B were 96.72%, 101.06%, 102.05%, and 99.03%, 100.18%, 100.28% in low, middle, and high concentrations, respectively. The average contents of schisandrin in serum and plasma were 11.063 2 and 12.883 7 ?g/mL, schisandrin B were 7.490 9 and 12.590 8 ?g/mL, respectively. Conclusion The main constitu-ents of Compound Wurenchun Capsules contained in plasma account for higher than the ones in serum.
ABSTRACT
AIM: To illuminate the therapeutic basis of Compound Wurenchun Capsules in combination with serum pharmacology,the lignans of this preparation migrating to blood of rats after oral administration having been accomplished. METHODS: By UPLC-MS/MS method, lignans migrating to blood were affirmed by comparing the extracted ion chromatography (EIC) of the serum containing drug with the ones of Compound Wurenchun Capsules, the control serum and control articles, correlated ion peak in mass-spectrogram were analyzed at the same time. RESULTS: Five lignans migrating to blood have been found, they are schisandrin, schisandrol B, schisantherin, deoxyschizandrin and schisandrin B. CONCLUSION: Five lignans above mentioned are likely the effective substances of Compound Wurenchun Capsules in human body. More study by means of combining with serum pharmacology will illuminate the therapeutic basis of this preparation.